It is still a trial, but the positive results are well-hoped. The administration of the therapeutic vaccine occurred at Pascale, the Institute of Cancer of Naples, which is, among other things, the leader of an international scientific project started 5 years ago and that today is showing the first results hoped. At the head of the project is Luigi Buonaguro, head of the departmental structure of immunoregulation of tumors. What is the Hepavac vaccine? The eighty-year-old patient object of the experimentation underway in Naples is affected by liver cancer. This type of tumour is characterized by antigens of hepatocellular carcinoma, that is, proteins that present in large quantities only on cancer cells.
The patient of Naples is not the only one to participate in the experimentation, in total the subjects are five. On them now the experts are evaluating the side effects, fundamental aspect to proceed with the tests. For now we know that the first four patients (one followed in Belgium and the other three at Negrar in Verona) showed minor side effects.
Hopes for the future The researchers, understandably cautious, are confident of achieving the desired results. "Hepavac will be the first vaccine in the world for Liver cancer candidate for subsequent large-scale experimentation to definitively test its efficacy and provide a therapeutic tool for patients with such a lethal tumour" conclude.
http://attivonews.com/arriva-il-vaccino-anti-cancro-in-italia-il-1-paziente-che-ha-ricevuto-la-somministrazione/
0 commenti:
Posta un commento